Table 1.
JAK inhibitors in clinical trial (phase I not included).
| JAK inhibitor | Target of the inhibitor | Disease in clinical trial | Phase of clinical trial | ClinicalTrial.gov (USA) number |
|---|---|---|---|---|
| Ruxolitinib (INC424) | JAK1,2 | Myeloproliferative neoplasms (MPN) | III | NCT00952289 |
| Polycythemia vera (PV) | III | NCT01243944 | ||
| Primary myelofibrosis (MF) | III | NCT02087059 | ||
| NCT00934544 | ||||
| II | NCT01732445 | |||
| NCT01795677 | ||||
| NCT01787552 | ||||
| NCT01693601 | ||||
| MF, Post-PV, Post-essential thrombocythemia (ET) myelofibrosis | III | NCT01969838 | ||
| II | NCT01392443 | |||
| NCT01445769 | ||||
| NCT00509899 | ||||
| MF, Acute lymphoblastic leukemia (ALL), MPN, Myelodysplastic syndrome (MDS) | II | NCT02158858 | ||
| Graft-vs-host disease (GVHD) | III | NCT03112603 | ||
| II | NCT02997280 | |||
| NCT03395340 | ||||
| NCT02953678 | ||||
| Vitiligo | II | NCT03099304 | ||
| ALL | II | NCT02723994 | ||
| AML/ALL | II | NCT01251965 | ||
| Myelomonocytic leukemia | II | NCT01776723 | ||
| T-cell ALL | II | NCT01712659 | ||
| Multiple myeloma | II | NCT00639002 | ||
| CML | II | NCT01751425 | ||
| Hodgkin's lymphoma | II | NCT02164500 | ||
| NCT01877005 | ||||
| Atopic dermatitis | II | NCT02001181 | ||
| Tofacitinib (CP-690,550) | JAK1,2,3 | RA | III | NCT02281552 |
| NCT00853385 | ||||
| II | NCT00147498 | |||
| Psoriasis | III | NCT01309737 | ||
| NCT01815424 | ||||
| NCT01186744 | ||||
| NCT01976364 | ||||
| Arthritis, RA | III | NCT01039688 | ||
| Ulcerative colitis | III | NCT01458574 | ||
| Alopecia areata (AA), Alopecia totalis (AT), Alopecia universalis (AU) | II | NCT02197455 | ||
| Kidney transplantation | II | NCT00658359 | ||
| NCT00483756 | ||||
| INCB052793 | JAK1 | Solid tumors, advanced malignancies, metastatic cancer | II | NCT02265510 |
| AZD4205 | JAK1 | Non-small cell lung cancer | II | NCT03450330 |
| TD-1473 | JAK1,2,3 | Crohn's disease | II | NCT03635112 |
| Givinostat (ITF2357) | JAK2 | MF | II | NCT00606307 |
| PV | II | NCT00928707 | ||
| MPN | II | NCT01761968 | ||
| Pacritinib | JAK2 | MF | II | NCT03645824 |
| Decernotinib (VX-509) | JAK3 | RA | II | NCT01590459 |
| NCT01754935 | ||||
| Baricitinib | JAK1,2 | GVHD | II | NCT02759731 |
| Giant cell arteritis | II | NCT03026504 | ||
| Lestauritinib (CEP-701) | JAK 2 | MF | II | NCT00494585 |
| BMS-911543 | JAK2 | MF | II | NCT01236352 |